Get answers to your questions about TYSABRI by selecting one of the topics below.
TYSABRI is a disease modifying therapy (DMT) that has been available to treat relapsing multiple sclerosis (MS) for over 15 years. DMTs may help:
It’s important to note that DMTs do not treat symptoms. Instead, they aim to work at the root of relapsing MS disease activity. Learn more.
We don’t fully understand how TYSABRI works. But it’s thought to play a role in preventing rogue immune cells from entering your central nervous system (CNS) and mistakenly attacking your nerve cells.
By keeping B and T cells in your bloodstream and blocking them from entering your CNS, TYSABRI may help reduce damage to your nerve cells. Watch a video to learn more about how TYSABRI is thought to work.
TYSABRI is a biologic medicine which means it’s made from living things like cells and proteins. When compared with its proposed biosimilar medicine, a biologic medicine can also be known as the "reference" medicine.
A biosimilar medicine has a similar structure and function to an FDA-approved biologic medicine. The FDA will compare the biosimilar against the reference medicine to ensure there are no significant differences.
There are many factors to keep in mind when you and your healthcare provider are considering treatment options for your relapsing MS. Some topics you may want to bring up to your healthcare team include:
A biosimilar medicine is not the same as a generic medicine. A biosimilar is a biologic medicine that is highly similar to an already-approved biologic medicine. This differs from generics, which have the same active ingredient as their reference medicine.
Both biosimilar and generic medicines do get compared to an original or reference product. Both medicines go through a thorough review process by the FDA to ensure there are no significant differences.
TYSABRI is administered every 28 days as an infusion by a trained healthcare professional. The actual infusion takes an hour.
For your first 12 infusions, you'll be asked to stay for an additional hour for routine observation. After your 12th infusion, your healthcare provider may decide to shorten or skip the observation period.
The TOUCH Prescribing Program is a risk monitoring program for anyone receiving TYSABRI. TOUCH ensures that you communicate closely with your healthcare team to monitor progressive multifocal leukoencephalopathy (PML) risk over time, so you can decide whether TYSABRI remains right for you. Your doctor, nurse, pharmacy, and infusion center are all part of the TOUCH program.
You can receive TYSABRI only through the TOUCH Prescribing Program. An infusion location can be in a doctor’s office, hospital, or at its own facility.
You may be treated with TYSABRI for as long as you and your healthcare team decide it is right for you. In the US, more than 40% of people being treated with TYSABRI have been using it for more than 5 years.*
*Of the 26,776 patients taking TYSABRI, 12,537 (46.8%) have been treated with TYSABRI for >5 years as of March 2023.
No, TYSABRI does not cause PML. However, taking TYSABRI can increase your risk of getting it. Many people have concerns about getting PML from taking TYSABRI, but it’s important to know that you can only get PML if you’ve been infected with the John Cunningham (JC) Virus. Your risk of getting PML is less than 1% regardless of JC Virus antibody status. Learn more about the JC Virus and PML.
Everyone’s risk of developing PML is different, so you should have a conversation with your healthcare team before starting TYSABRI.
TYSABRI can cause serious side effects, which include:
The most common side effects are:
If you experience any side effect that bothers you or does not go away, tell your doctor.
Biogen Support Services is here to help you throughout your time on TYSABRI. From the moment you start treatment, Biogen Support Services provides:
To get started, call 1-800-456-2255 Monday-Friday from 8:30 AM to 8 PM ET. Remember, your healthcare team is always your best source of information.